Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06846606 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
A Phase 1 study of Refractory Myelodysplastic Syndromes and Relapsed/Refractory AML, sponsored by Auron Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 9
- Study locations
NCT06846606 is a Phase 1 study of Refractory Myelodysplastic Syndromes and Relapsed/Refractory AML that is active but no longer recruiting, run by Auron Therapeutics. The registered enrollment target is 34 participants. The trial reports 9 study locations across 8 states.
The verdict
NCT06846606, a Phase 1 study of Refractory Myelodysplastic Syndromes and Relapsed/Refractory AML, is active but no longer recruiting, sponsored by Auron Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 9
- Study locations
Study Summary
This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703 administered orally in subjects with advanced hematologic malignancies.
Conditions Studied
Interventions
- DRUG AUTX-703
Study Locations (9)
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Memorial Sloan Kettering Cancer Center - New York
California
- City of Hope National Medical Center - Duarte
Florida
- H Lee Moffitt Cancer Center and Research Institute - Tampa
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Ohio
- Ohio State University, The James Comprehensive Cancer - Columbus
Pennsylvania
- UPENN Perelman Center for Advanced Medicine - Philadelphia
Tennessee
- Sarah Cannon Center for Blood Cancer at TriStar Centennia - Nashville
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06846606
The ClinicalTrials.gov registry entry for NCT06846606 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Auron Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Refractory Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which AUTX-703 is the first listed.
NCT06846606 reports 9 study locations spanning 8 distinct geographic areas - top geographies include New York, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06846606 about?
NCT06846606 is a clinical study titled "Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS". This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703 administered orally in subjects with advanced hematologic malignancies.
What is the current status of trial NCT06846606?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2025-05-01. Estimated completion is 2028-06.
What conditions does trial NCT06846606 study?
This clinical trial studies the following conditions: Refractory Myelodysplastic Syndromes, Relapsed/Refractory AML, Relapsed Myelodysplastic Syndromes, Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML).
What interventions are being tested in trial NCT06846606?
The interventions under investigation include: AUTX-703 (DRUG).
Who is sponsoring clinical trial NCT06846606?
This trial is sponsored by Auron Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06846606 being conducted?
This trial has 9 study locations across California, Florida, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Refractory Myelodysplastic Syndromes
All registered trials for this condition
Relapsed/Refractory AML
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.